Neratinib and Ruxolitinib for Metastatic Triple-Negative Breast Cancer
This study is testing a combination of two oral medications, neratinib and ruxolitinib, for women with metastatic triple-negative breast cancer (mTNBC). This is a type of breast cancer that doesn't respond to common hormone or HER2-targeted therapies. You may be able to join if you are a woman aged 18 or older with mTNBC that has been previously treated with standard chemotherapy. The researchers want to see how safe and effective this drug combination is, especially for chest wall recurrence. They will measure how many patients respond to the treatment over 18 months. The study is looking for about 20 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 20 participants.
- What's involved
- Participants will take neratinib once daily and ruxolitinib twice daily. Dosing for neratinib will follow standard dose escalation procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, Objective Response Rate, will be measured at 18 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Joyce A O'Shaughnessy, MD · PRINCIPAL_INVESTIGATOR · Baylor Scott & White The Heart Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Objective Response Rate18 months
Calculate objective response rate (CR+PR) associated with neratinib in combination ruxolitinib. Objective response rate will be calculated by defining the proportion of patients who have a complete or partial response to the study therapy, as determined by the treating physician.